← All trials
NCT05296746
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 3, 2022
- Primary completion
- Feb 1, 2030
- Completion date
- Jul 1, 2030
- First posted
- Mar 25, 2022
- Last posted
- Jul 8, 2022
- Enrollment
- 530
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- SOLTI Breast Cancer Research GroupLead sponsor
- University of BarcelonaOverall official - principal investigator
- Curie InstituteOverall official - principal investigator
- Fundacion Instituto Valenciano de OncologiaOverall official - principal investigator
- UNICANCERCollaborator
- Curie InstituteOfficial
- Fundacion Instituto Valenciano de OncologiaOfficial
- University of BarcelonaOfficial
- NovartisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.